Perampanel Shows Promise for Reducing Seizures in Lennox-Gastaut Syndrome

Source: Epilepsy & behavior : E&B

Summary

Researchers studied the effectiveness and safety of a medication called perampanel in patients with Lennox-Gastaut syndrome (LGS), a severe form of epilepsy that often starts in childhood. LGS is known for causing multiple types of seizures that are hard to control with standard treatments. The study included data from 14 different studies, which involved a total of 330 patients, to see how well perampanel worked in reducing seizures and what side effects it might cause.

The key findings showed that about 46.5% of patients experienced a significant reduction in their seizures (at least 50% fewer seizures), while only 4.9% became completely seizure-free. Some patients also reported side effects, including sleepiness, irritability, and psychiatric symptoms. While the results indicate that perampanel can help reduce seizures for some patients, the overall effectiveness varied, and there were notable side effects that caregivers should be aware of.

These findings are important because they suggest that perampanel may be a useful option for managing seizures in patients with LGS, especially when other treatments have failed. However, the study also had limitations, such as the variability in the data and the fact that many of the studies were retrospective, meaning they looked back at past patient records rather than conducting new trials. This highlights the need for more high-quality research to better understand how well perampanel works and its safety profile in this specific group of patients.

Original source